Furthermore, Ibrutinib inhibits IL2 inducible T cell kinase and EGFR, and in a relapse/refractory MCL pivotal phase 2 study, Ibrutinib demonstrated Overall response rate of 67% [150] and showed promising results in relapse MCL phase III MCL3001 trial NCT0164021 with an improved progression free survival [151]. Here, ITK is linked to mantle cell lymphoma.